Shaunak S, Wilkins A, Pilling J B, Dick D J
Department of Neurology, Norfolk and Norwich Hospital, UK.
J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):79-81. doi: 10.1136/jnnp.66.1.79.
Three patients with Parkinson's disease are described who developed pericardial, retroperitoneal, and pleural fibrosis associated with pergolide treatment. Surgical intervention was required in all three cases, either to reach a tissue diagnosis or for potentially life threatening complications. Symptoms emerged on average 2 years after the institution of treatment, and were sufficiently non-specific to cause significant delays in diagnosis in all cases. The erythrocyte sedimentation rate (ESR) was raised in the two patients in whom it was measured. Serosal fibrosis is a rarely reported adverse effect of pergolide treatment, although it is well described with other dopamine agonists. We suggest that patients with Parkinson's disease who receive pergolide treatment should be regularly monitored for the development of such complications.
本文描述了3例帕金森病患者，他们在接受培高利特治疗后出现了心包、腹膜后和胸膜纤维化。所有3例患者均需要手术干预，要么是为了获得组织诊断，要么是为了处理可能危及生命的并发症。症状平均在治疗开始后2年出现，且症状缺乏特异性，导致所有病例的诊断均出现显著延迟。在检测的2例患者中，红细胞沉降率（ESR）升高。浆膜纤维化是培高利特治疗很少报道的不良反应，尽管其他多巴胺激动剂也有相关报道。我们建议，接受培高利特治疗的帕金森病患者应定期监测此类并发症的发生。
